Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Advances in immunotherapy have brought significant therapeutic benefits to many cancer patients. Nonetheless, many cancer types are refractory to current immunotherapeutic approaches, meaning that further targets are required to increase the number of patients who benefit from these technologies. Pr...

Full description

Bibliographic Details
Main Author: Robert J. Salmond
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/13/3/231
_version_ 1827354827896651776
author Robert J. Salmond
author_facet Robert J. Salmond
author_sort Robert J. Salmond
collection DOAJ
description Advances in immunotherapy have brought significant therapeutic benefits to many cancer patients. Nonetheless, many cancer types are refractory to current immunotherapeutic approaches, meaning that further targets are required to increase the number of patients who benefit from these technologies. Protein tyrosine phosphatases (PTPs) have long been recognised to play a vital role in the regulation of cancer cell biology and the immune response. In this review, we summarize the evidence for both the pro-tumorigenic and tumour-suppressor function of non-receptor PTPs in cancer cells and discuss recent data showing that several of these enzymes act as intracellular immune checkpoints that suppress effective tumour immunity. We highlight new data showing that the deletion of inhibitory PTPs is a rational approach to improve the outcomes of adoptive T cell-based cancer immunotherapies and describe recent progress in the development of PTP inhibitors as anti-cancer drugs.
first_indexed 2024-03-08T03:59:17Z
format Article
id doaj.art-1928387138264575864309430ec520eb
institution Directory Open Access Journal
issn 2073-4409
language English
last_indexed 2024-03-08T03:59:17Z
publishDate 2024-01-01
publisher MDPI AG
record_format Article
series Cells
spelling doaj.art-1928387138264575864309430ec520eb2024-02-09T15:09:39ZengMDPI AGCells2073-44092024-01-0113323110.3390/cells13030231Targeting Protein Tyrosine Phosphatases to Improve Cancer ImmunotherapiesRobert J. Salmond0Leeds Institute of Medical Research at St. James’s, School of Medicine, University of Leeds, Leeds LS9 7TF, UKAdvances in immunotherapy have brought significant therapeutic benefits to many cancer patients. Nonetheless, many cancer types are refractory to current immunotherapeutic approaches, meaning that further targets are required to increase the number of patients who benefit from these technologies. Protein tyrosine phosphatases (PTPs) have long been recognised to play a vital role in the regulation of cancer cell biology and the immune response. In this review, we summarize the evidence for both the pro-tumorigenic and tumour-suppressor function of non-receptor PTPs in cancer cells and discuss recent data showing that several of these enzymes act as intracellular immune checkpoints that suppress effective tumour immunity. We highlight new data showing that the deletion of inhibitory PTPs is a rational approach to improve the outcomes of adoptive T cell-based cancer immunotherapies and describe recent progress in the development of PTP inhibitors as anti-cancer drugs.https://www.mdpi.com/2073-4409/13/3/231protein tyrosine phosphatase (non-receptor type)cancer immunotherapytumour suppressoroncogeneT cellscell signalling
spellingShingle Robert J. Salmond
Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies
Cells
protein tyrosine phosphatase (non-receptor type)
cancer immunotherapy
tumour suppressor
oncogene
T cells
cell signalling
title Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies
title_full Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies
title_fullStr Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies
title_full_unstemmed Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies
title_short Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies
title_sort targeting protein tyrosine phosphatases to improve cancer immunotherapies
topic protein tyrosine phosphatase (non-receptor type)
cancer immunotherapy
tumour suppressor
oncogene
T cells
cell signalling
url https://www.mdpi.com/2073-4409/13/3/231
work_keys_str_mv AT robertjsalmond targetingproteintyrosinephosphatasestoimprovecancerimmunotherapies